384 related articles for article (PubMed ID: 16552630)
1. A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.
de Winter W; DeJongh J; Post T; Ploeger B; Urquhart R; Moules I; Eckland D; Danhof M
J Pharmacokinet Pharmacodyn; 2006 Jun; 33(3):313-43. PubMed ID: 16552630
[TBL] [Abstract][Full Text] [Related]
2. Free fatty acid kinetics during long-term treatment with pioglitazone added to sulfonylurea or metformin in Type 2 diabetes.
Roden M; Mariz S; Brazzale AR; Pacini G
J Intern Med; 2009 Apr; 265(4):476-87. PubMed ID: 19298459
[TBL] [Abstract][Full Text] [Related]
3. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.
Tan M; Johns D; González Gálvez G; Antúnez O; Fabián G; Flores-Lozano F; Zúñiga Guajardo S; Garza E; Morales H; Konkoy C; Herz M;
Clin Ther; 2004 May; 26(5):680-93. PubMed ID: 15220012
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus.
Roden M; Laakso M; Johns D; Widel M; Urquhart R; Richardson C; Mariz S; Tan MH
Diabet Med; 2005 Aug; 22(8):1101-6. PubMed ID: 16026380
[TBL] [Abstract][Full Text] [Related]
5. Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes.
Perriello G; Pampanelli S; Di Pietro C; Brunetti P;
Diabet Med; 2006 Mar; 23(3):246-52. PubMed ID: 16492206
[TBL] [Abstract][Full Text] [Related]
6. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
7. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.
Charbonnel B; Schernthaner G; Brunetti P; Matthews DR; Urquhart R; Tan MH; Hanefeld M
Diabetologia; 2005 Jun; 48(6):1093-104. PubMed ID: 15889234
[TBL] [Abstract][Full Text] [Related]
9. Effects of pioglitazone add-on to gliclazide and metformin on glycemic control in patients with type 2 diabetes.
Al-Azzam SI; Alomari M; Khader YS; Almahasneh FA; Muflih SM; Altawalbeh S
Endocr Res; 2012; 37(1):7-11. PubMed ID: 21977974
[TBL] [Abstract][Full Text] [Related]
10. 2-year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with type 2 diabetes.
Seufert J; Urquhart R
Diabetes Res Clin Pract; 2008 Mar; 79(3):453-60. PubMed ID: 18160120
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone.
Pareek A; Chandurkar N; Thomas N; Viswanathan V; Deshpande A; Gupta OP; Shah A; Kakrani A; Bhandari S; Thulasidharan NK; Saboo B; Devaramani S; Vijaykumar NB; Sharma S; Agrawal N; Mahesh M; Kothari K
Curr Med Res Opin; 2014 Jul; 30(7):1257-66. PubMed ID: 24669876
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes.
Belcher G; Lambert C; Edwards G; Urquhart R; Matthews DR
Diabetes Res Clin Pract; 2005 Oct; 70(1):53-62. PubMed ID: 16002175
[TBL] [Abstract][Full Text] [Related]
13. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
Charbonnel BH; Matthews DR; Schernthaner G; Hanefeld M; Brunetti P;
Diabet Med; 2005 Apr; 22(4):399-405. PubMed ID: 15787663
[TBL] [Abstract][Full Text] [Related]
14. Earlier triple therapy with pioglitazone in patients with type 2 diabetes.
Charpentier G; Halimi S;
Diabetes Obes Metab; 2009 Sep; 11(9):844-54. PubMed ID: 19614944
[TBL] [Abstract][Full Text] [Related]
15. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
[TBL] [Abstract][Full Text] [Related]
16. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.
Bosi E; Ellis GC; Wilson CA; Fleck PR
Diabetes Obes Metab; 2011 Dec; 13(12):1088-96. PubMed ID: 21733058
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of efficacy and tolerability of gliclazide and metformin combination: a multicentric study in patients with type 2 diabetes mellitus uncontrolled on monotherapy with sulfonylurea or metformin.
Pareek A; Chandurkar N; Zawar S; Agrawal N
Am J Ther; 2010; 17(6):559-65. PubMed ID: 20093927
[TBL] [Abstract][Full Text] [Related]
18. Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens.
Charbonnel B; Roden M; Urquhart R; Mariz S; Johns D; Mihm M; Widel M; Tan M
Diabetologia; 2005 Mar; 48(3):553-60. PubMed ID: 15739120
[TBL] [Abstract][Full Text] [Related]
19. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.
Pavo I; Jermendy G; Varkonyi TT; Kerenyi Z; Gyimesi A; Shoustov S; Shestakova M; Herz M; Johns D; Schluchter BJ; Festa A; Tan MH
J Clin Endocrinol Metab; 2003 Apr; 88(4):1637-45. PubMed ID: 12679450
[TBL] [Abstract][Full Text] [Related]
20. The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus.
Erdem G; Dogru T; Tasci I; Bozoglu E; Muhsiroglu O; Tapan S; Ercin CN; Sonmez A
Diabetes Res Clin Pract; 2008 Nov; 82(2):214-8. PubMed ID: 18778865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
